{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:24:25Z","timestamp":1790205865760,"version":"4.1.0"},"reference-count":160,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.ncl.2008.05.003","type":"journal-article","created":{"date-parts":[[2008,9,7]],"date-time":"2008-09-07T18:01:52Z","timestamp":1220810512000},"page":"65-83","source":"Crossref","is-referenced-by-count":29,"special_numbering":"S","title":["Adverse Events from the Treatment of Parkinson's Disease"],"prefix":"10.1016","volume":"26","author":[{"given":"Kelvin L.","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2008.05.003_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/mds.870060211","article-title":"Gastrointestinal symptoms in Parkinson's disease","volume":"6","author":"Edwards","year":"1991","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib2","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1212\/WNL.50.6_Suppl_6.S11","article-title":"Mechanism of action of dopaminergic agents in Parkinson's disease","volume":"50","author":"Koller","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib3","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0140-6736(79)91003-1","article-title":"Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease","volume":"1","author":"Agid","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2008.05.003_bib4","first-page":"671","volume":"36","author":"Pollak","year":"1981","journal-title":"Therapie"},{"key":"10.1016\/j.ncl.2008.05.003_bib5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00002826-198610000-00004","article-title":"Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease","volume":"9","author":"Langdon","year":"1986","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2008.05.003_bib6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/01.WNF.0000220824.57769.E5","article-title":"Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease","volume":"29","author":"Kolls","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2008.05.003_bib7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1474-4422(06)70411-2","article-title":"Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism","volume":"5","author":"Schrag","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib9","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s004150050530","article-title":"Risk factors for levodopa-induced dyskinesias in Parkinson's disease","volume":"246","author":"Grandas","year":"1999","journal-title":"J Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib10","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1468-1331.2005.01096.x","article-title":"Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study","volume":"12","author":"Pechevis","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib11","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib12","first-page":"163","article-title":"Patterns of dystonia in response to L-Dopa therapy for Parkinson's disease","volume":"52","author":"Muenter","year":"1977","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ncl.2008.05.003_bib13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","article-title":"Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004","volume":"20","author":"Goetz","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","article-title":"Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease","volume":"15","author":"Luginger","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib16","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","article-title":"Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study","volume":"56","author":"Metman","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","article-title":"The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study","volume":"23","author":"Snow","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2008.05.003_bib18","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2008.05.003_bib19","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2008.05.003_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJMoa000827","article-title":"Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease","volume":"345","author":"Deep Brain Stimulation for Parkinson's Disease Study Group","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ncl.2008.05.003_bib24","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3171\/jns.2003.99.4.0701","article-title":"Long-term motor effect of unilateral pallidal stimulation in 26 patients with advanced Parkinson disease","volume":"99","author":"Visser-Vandewalle","year":"2003","journal-title":"J Neurosurg"},{"issue":"Suppl 14","key":"10.1016\/j.ncl.2008.05.003_bib25","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1002\/mds.20962","article-title":"Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes","volume":"21","author":"Kleiner-Fisman","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/WNL.55.2.281","article-title":"Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis","volume":"55","author":"Arnulf","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/mds.870050404","article-title":"Sleep disorders and sleep effect in Parkinson's disease","volume":"5","author":"Factor","year":"1990","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF02257678","article-title":"Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease","volume":"5","author":"Van Hilten","year":"1993","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.ncl.2008.05.003_bib29","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.10429","article-title":"Sleepiness in Parkinson's disease: a controlled study","volume":"18","author":"Brodsky","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/jnnp.74.7.956","article-title":"Olfactory deficits and sleep disturbances in Parkinson's disease: a case control survey","volume":"74","author":"Henderson","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2008.05.003_bib31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mds.10365","article-title":"Increased daytime sleepiness in Parkinson's disease: a questionnaire survey","volume":"18","author":"Hogl","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib32","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1212\/WNL.58.7.1019","article-title":"Parkinson's disease and sleepiness: an integral part of PD","volume":"58","author":"Arnulf","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib33","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/mds.10193","article-title":"Excessive daytime sleepiness in de novo and treated Parkinson's disease","volume":"17","author":"Fabbrini","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib34","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1001\/archneur.59.6.986","article-title":"Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease","volume":"59","author":"O'Suilleabhain","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.287.4.455","article-title":"Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group","volume":"287","author":"Hobson","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ncl.2008.05.003_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archneur.61.1.97","article-title":"Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists","volume":"61","author":"Razmy","year":"2004","journal-title":"Arch Neurol."},{"key":"10.1016\/j.ncl.2008.05.003_bib37","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/archneur.62.8.1242","article-title":"Sudden uncontrollable somnolence and medication use in Parkinson disease","volume":"62","author":"Avorn","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib38","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1212\/01.wnl.0000233980.25978.9d","article-title":"Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?","volume":"67","author":"Gjerstad","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jnnp.2006.100370","article-title":"Insomnia in Parkinson's disease: frequency and progression over time","volume":"78","author":"Gjerstad","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.ncl.2008.05.003_bib40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF00435308","article-title":"The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man","volume":"70","author":"Thornton","year":"1980","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ncl.2008.05.003_bib41","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2006.05.004","article-title":"The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography","volume":"248","author":"Dhawan","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ncl.2008.05.003_bib42","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/mds.10167","article-title":"Sleep disorders in Parkinson's disease","volume":"17","author":"Kumar","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib43","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1212\/WNL.63.8_suppl_3.S12","article-title":"Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease","volume":"63","author":"Poewe","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib44","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/mds.20624","article-title":"Sleep apnea syndrome in Parkinson's disease. A case-control study in 49 patients","volume":"20","author":"Diederich","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/jnnp.67.4.492","article-title":"Range of neuropsychiatric disturbances in patients with Parkinson's disease","volume":"67","author":"Aarsland","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2008.05.003_bib46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/archneur.1996.00550020087019","article-title":"The occurrence of depression in Parkinson's disease. A community-based study","volume":"53","author":"Tandberg","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib47","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/archneur.1992.00530290076015","article-title":"A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender","volume":"49","author":"Mayeux","year":"1992","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","article-title":"Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study","volume":"56","author":"Aarsland","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib49","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial","volume":"284","author":"Parkinson Study Group","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ncl.2008.05.003_bib50","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ncl.2008.05.003_bib51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease","volume":"68","author":"Watts","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib52","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","article-title":"Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole","volume":"52","author":"Frucht","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib53","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/bmj.324.7352.1483","article-title":"Sleep attacks in patients taking dopamine agonists: review","volume":"324","author":"Homann","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.ncl.2008.05.003_bib54","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/1531-8257(200003)15:2<212::AID-MDS1002>3.0.CO;2-6","article-title":"Waking up to sleep episodes in Parkinson's disease","volume":"15","author":"Olanow","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib55","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mds.10417","article-title":"Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease","volume":"18","author":"Paus","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib56","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/mds.20412","article-title":"Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel","volume":"20","author":"Meindorfner","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib57","first-page":"32","article-title":"Sustained-release levodopa in parkinsonian patients with nocturnal disabilities","volume":"93","author":"Van den Kerchove","year":"1993","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.ncl.2008.05.003_bib58","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mds.10639","article-title":"Improvement of sleep quality in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus","volume":"19","author":"Hjort","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib59","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mds.10390","article-title":"Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease","volume":"18","author":"Adler","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib60","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/sleep\/25.8.62","article-title":"Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial","volume":"25","author":"Hogl","year":"2002","journal-title":"Sleep"},{"key":"10.1016\/j.ncl.2008.05.003_bib61","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/jnnp.2005.065870","article-title":"Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial","volume":"76","author":"Ondo","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2008.05.003_bib62","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archneur.64.8.1089","article-title":"Medication-related impulse control and repetitive behaviors in Parkinson disease","volume":"64","author":"Voon","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib63","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.parkreldis.2005.06.005","article-title":"Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy","volume":"11","author":"Klos","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib64","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1212\/01.wnl.0000238503.20816.13","article-title":"Prevalence of repetitive and reward-seeking behaviors in Parkinson disease","volume":"67","author":"Voon","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib65","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.wnl.0000218206.20920.4d","article-title":"Prospective prevalence of pathologic gambling and medication association in Parkinson disease","volume":"66","author":"Voon","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib66","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0006-3223(94)90636-X","article-title":"Punding on levodopa","volume":"36","author":"Friedman","year":"1994","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ncl.2008.05.003_bib67","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/mds.21072","article-title":"Prevalence of pathological gambling in patients with Parkinson's disease","volume":"21","author":"Avanzi","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib68","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/mds.21110","article-title":"Problematic gambling on dopamine agonists: Not such a rarity","volume":"21","author":"Grosset","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib69","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.63.7.969","article-title":"Association of dopamine agonist use with impulse control disorders in Parkinson disease","volume":"63","author":"Weintraub","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib70","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","article-title":"Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome","volume":"19","author":"Evans","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib71","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/mds.21296","article-title":"Punding prevalence in Parkinson's disease","volume":"22","author":"Miyasaki","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib72","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies","volume":"68","author":"Giovannoni","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2008.05.003_bib73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/mds.20288","article-title":"Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease","volume":"20","author":"Pezzella","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib74","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.neubiorev.2005.02.004","article-title":"The role of dopamine in conditioning and latent inhibition: what, when, where and how?","volume":"29","author":"Young","year":"2005","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.ncl.2008.05.003_bib75","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson disease","volume":"62","author":"Dodd","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib76","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0269881106073109","article-title":"New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset","volume":"21","author":"Giladi","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.ncl.2008.05.003_bib77","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/wnf.0b013e31804c780e","article-title":"Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome","volume":"30","author":"Driver-Dunckley","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2008.05.003_bib78","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/mds.21303","article-title":"Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis","volume":"22","author":"Evans","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib79","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.parkreldis.2006.10.001","article-title":"Pathological gambling associated with dopamine agonist use in restless legs syndrome","volume":"13","author":"Quickfall","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib80","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.wnl.0000252368.25106.b6","article-title":"Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists","volume":"68","author":"Tippmann-Peikert","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib81","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/archneur.64.2.212","article-title":"Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease","volume":"64","author":"Voon","year":"2007","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2008.05.003_bib82","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.21770","article-title":"Long-term follow-up of impulse control disorders in Parkinson's disease","volume":"23","author":"Mamikonyan","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib83","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/01.WNL.0000076478.45005.EC","article-title":"Pathological gambling associated with dopamine agonist therapy in Parkinson's disease","volume":"61","author":"Driver-Dunckley","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib84","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mds.10625","article-title":"Disabling repetitive behaviors in Parkinson's disease","volume":"19","author":"Kurlan","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib85","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.parkreldis.2003.08.002","article-title":"Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease","volume":"10","author":"Miwa","year":"2004","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib86","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/mds.21098","article-title":"Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation","volume":"21","author":"Ardouin","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib87","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/mds.20501","article-title":"Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation","volume":"20","author":"Witjas","year":"2005","journal-title":"Mov Disord"},{"issue":"Pt 4","key":"10.1016\/j.ncl.2008.05.003_bib88","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors","volume":"123","author":"Fenelon","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2008.05.003_bib89","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","article-title":"Prospective study of hallucinations and delusions in Parkinson's disease","volume":"70","author":"Holroyd","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.ncl.2008.05.003_bib90","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archneur.1996.00550120077019","article-title":"Visual hallucinations associated with Parkinson disease","volume":"53","author":"Sanchez-Ramos","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib91","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib92","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.wnf.0000180228.77802.32","article-title":"Drug-induced psychosis in parkinson disease: phenomenology and correlations among psychosis rating instruments","volume":"28","author":"Chou","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2008.05.003_bib93","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/jnnp.64.4.533","article-title":"Auditory hallucinations in Parkinson's disease","volume":"64","author":"Inzelberg","year":"1998","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2008.05.003_bib94","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/01.WNL.0000148479.10865.FE","article-title":"Hallucinations and sleep disorders in PD: six-year prospective longitudinal study","volume":"64","author":"Goetz","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib95","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000129843.15756.A3","article-title":"Psychiatric comorbidities in patients with Parkinson disease and psychosis","volume":"63","author":"Marsh","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib96","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1212\/WNL.55.11.1753","article-title":"Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease","volume":"55","author":"Dewey","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib97","first-page":"115","article-title":"Parkinson's disease: drug-induced psychiatric states","volume":"65","author":"Factor","year":"1995","journal-title":"Adv Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib98","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2005.06.011","article-title":"Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability","volume":"12","author":"Schrag","year":"2006","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib99","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1532-5415.2000.tb06891.x","article-title":"Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study","volume":"48","author":"Aarsland","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ncl.2008.05.003_bib100","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","article-title":"Risk factors for nursing home placement in advanced Parkinson's disease","volume":"43","author":"Goetz","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib101","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/01.WNL.0000068010.82167.CF","article-title":"Longitudinal outcome of Parkinson's disease patients with psychosis","volume":"60","author":"Factor","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib102","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/WNL.45.4.669","article-title":"Mortality and hallucinations in nursing home patients with advanced Parkinson's disease","volume":"45","author":"Goetz","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib103","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1517\/13543784.15.4.339","article-title":"Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs","volume":"15","author":"Chou","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ncl.2008.05.003_bib104","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","article-title":"Practice parameter: evaluation and treatment of depression, psychosis and dementia in Parkinson's disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Miyasaki","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ncl.2008.05.003_bib106","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: a randomized, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2008.05.003_bib107","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.10374","article-title":"Long-term outcome of quetiapine use for psychosis among Parkinsonian patients","volume":"18","author":"Fernandez","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib108","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/mds.10176","article-title":"The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia","volume":"17","author":"Reddy","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib109","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis","volume":"29","author":"Merims","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2008.05.003_bib110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis","volume":"27","author":"Morgante","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2008.05.003_bib111","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blinded, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease","volume":"20","author":"Ondo","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib112","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine in psychotic Parkinson's disease patients; a double-blinded labeled study of 3 months' duration","volume":"22","author":"Rabey","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib113","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","article-title":"Olanzapine in the treatment of Dopamimetic-induced psychosis in patients with Parkinson's disease","volume":"52","author":"Breier","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ncl.2008.05.003_bib114","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","article-title":"Olanzapine and clozapine: comparative effects on motor function in hallucination PD patients","volume":"55","author":"Goetz","year":"2000","journal-title":"Neurology"},{"issue":"8923","key":"10.1016\/j.ncl.2008.05.003_bib115","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(94)92114-8","article-title":"Risperidone in Parkinson's disease","volume":"344","author":"Ford","year":"1994","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ncl.2008.05.003_bib116","first-page":"556","article-title":"Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes","volume":"56","author":"Rich","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2008.05.003_bib117","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mds.870120423","article-title":"Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study","volume":"12","author":"Meco","year":"1997","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.ncl.2008.05.003_bib118","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/1531-8257(200003)15:2<301::AID-MDS1014>3.0.CO;2-2","article-title":"Risperidone treatment of drug-related psychosis in patients with Parkinsonism","volume":"15","author":"Leopold","year":"2000","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.ncl.2008.05.003_bib119","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9","article-title":"Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial","volume":"15","author":"Mohr","year":"2000","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2008.05.003_bib120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002826-200401000-00003","article-title":"Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience","volume":"27","author":"Fernandez","year":"2004","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"10.1016\/j.ncl.2008.05.003_bib121","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/mds.21091","article-title":"Open-label flexible dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease","volume":"21","author":"Friedman","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib122","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ncl.2008.05.003_bib123","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/WNL.24.1.46","article-title":"Amantadine hydrochloride: alteration in peripheral circulation","volume":"24","author":"Pearce","year":"1974","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib124","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-9343(93)90160-Q","article-title":"Edema\u2212an infrequently recognized complication of bromocriptine and other ergot dopaminergic drugs","volume":"94","author":"Blackard","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.ncl.2008.05.003_bib125","first-page":"245","article-title":"Refractory generalized edema: an infrequent complication of long-term pergolide treatment for Parkinson disease","volume":"28","author":"Bianchi","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2008.05.003_bib126","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1159\/000029576","article-title":"Pergolide-induced dyspnea, bilateral pleural effusion and peripheral edema","volume":"67","author":"Varsano","year":"2000","journal-title":"Respiration"},{"key":"10.1016\/j.ncl.2008.05.003_bib127","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1212\/01.wnl.0000265593.34438.00","article-title":"Risk factors for somnolence, edema, and hallucinations in early Parkinson disease","volume":"69","author":"Biglan","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib128","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archneur.64.6.noc60158","article-title":"Risk factors for the development of pedal edema in patients using pramipexole","volume":"64","author":"Kleiner-Fisman","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib129","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archneur.57.5.729","article-title":"Clinical characteristics of pramipexole-induced peripheral edema","volume":"57","author":"Tan","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib130","first-page":"169","article-title":"The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease","volume":"21","author":"Schrag","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ncl.2008.05.003_bib131","first-page":"1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib132","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.ede.0000229445.90471.5e","article-title":"Malignant melanoma and other types of cancer preceding Parkinson disease","volume":"17","author":"Olsen","year":"2006","journal-title":"Epidemiology"},{"key":"10.1016\/j.ncl.2008.05.003_bib133","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.bjc.6602279","article-title":"Atypical cancer pattern in patients with Parkinson's disease","volume":"92","author":"Olsen","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ncl.2008.05.003_bib134","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.cmr.0000215043.61306.d7","article-title":"Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature","volume":"16","author":"Zanetti","year":"2006","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ncl.2008.05.003_bib135","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/ana.410170514","article-title":"Low cancer rates among patients with Parkinson's disease","volume":"17","author":"Jansson","year":"1985","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib136","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1136\/bmj.310.6993.1500","article-title":"Occurrence of different cancers in patients with Parkinson's disease","volume":"310","author":"Moller","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.ncl.2008.05.003_bib137","first-page":"556","article-title":"Multiple primary melanoma following administration of levodopa","volume":"93","author":"Skibba","year":"1972","journal-title":"Arch Pathol"},{"key":"10.1016\/j.ncl.2008.05.003_bib138","first-page":"2327","article-title":"Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine","volume":"49","author":"Kable","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.ncl.2008.05.003_bib139","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1353-8020(03)00040-3","article-title":"Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?","volume":"9","author":"Fiala","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib140","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1345\/aph.19150","article-title":"Levodopa therapy and the risk of malignant melanoma","volume":"34","author":"Siple","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ncl.2008.05.003_bib141","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mds.21273","article-title":"Malignant melanoma in early Parkinson's disease: the DATATOP trial","volume":"22","author":"Constantinescu","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib142","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/mds.21397","article-title":"Treatment with levodopa and risk for malignant melanoma","volume":"22","author":"Olsen","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib143","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1212\/01.wnl.0000184520.21744.a2","article-title":"Education and occupations preceding Parkinson disease: a population-based case-control study","volume":"65","author":"Frigerio","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib144","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/ije\/19.4.801","article-title":"Malignant melanoma in England: risks associated with naevi, freckles, social class, hair colour, and sunburn","volume":"19","author":"Elwood","year":"1990","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ncl.2008.05.003_bib145","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1055-9965.EPI-07-0038","article-title":"A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease","volume":"16","author":"Driver","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ncl.2008.05.003_bib146","first-page":"879","article-title":"Diet, body size and micronutrient status in Parkinson's disease","volume":"46","author":"Abbott","year":"1992","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.ncl.2008.05.003_bib147","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ana.10577","article-title":"Weight loss in Parkinson's disease","volume":"53","author":"Chen","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib148","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/mds.20837","article-title":"Predictors of weight loss in Parkinson's disease","volume":"21","author":"Uc","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2008.05.003_bib149","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0002-8223(95)00269-3","article-title":"Weight change and body composition in patients with Parkinson's disease","volume":"95","author":"Beyer","year":"1995","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.ncl.2008.05.003_bib150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0022-510X(76)90253-7","article-title":"Weight loss in patients treated long-term with levodopa. Metabolic aspects","volume":"30","author":"Vardi","year":"1976","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ncl.2008.05.003_bib151","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-0404.2004.00307.x","article-title":"Factors of importance for weight loss in elderly patients with Parkinson's disease","volume":"110","author":"Lorefalt","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ncl.2008.05.003_bib152","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF02251202","article-title":"Increased prevalence of undernutrition in Parkinson's disease and its relationship to clinical disease parameters","volume":"5","author":"Markus","year":"1993","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.ncl.2008.05.003_bib153","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/ageing\/23.2.142","article-title":"A study of the nutritional status of elderly patients with Parkinson's disease","volume":"23","author":"Davies","year":"1994","journal-title":"Age Ageing"},{"key":"10.1016\/j.ncl.2008.05.003_bib154","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/cs0830199","article-title":"Raised resting energy expenditure in Parkinson's disease and its relationship to muscle rigidity","volume":"83","author":"Markus","year":"1992","journal-title":"Clin Sci (Lond)."},{"key":"10.1016\/j.ncl.2008.05.003_bib155","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1136\/bmj.301.6763.1256","article-title":"Increased energy expenditure in Parkinson's disease","volume":"301","author":"Levi","year":"1990","journal-title":"BMJ"},{"key":"10.1016\/j.ncl.2008.05.003_bib156","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.48.1.88","article-title":"Free-living daily energy expenditure in patients with Parkinson's disease","volume":"48","author":"Toth","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2008.05.003_bib157","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ana.410410624","article-title":"Neuropsychological and behavioral changes and weight gain after medial pallidotomy","volume":"41","author":"Lang","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib158","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1034\/j.1600-0404.2000.101002079.x","article-title":"Weight gain following unilateral pallidotomy in Parkinson's disease","volume":"101","author":"Ondo","year":"2000","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ncl.2008.05.003_bib159","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ana.10517","article-title":"Randomized trial of pallidotomy versus medical therapy for Parkinson's disease","volume":"53","author":"Vitek","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2008.05.003_bib160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1212\/WNL.53.1.85","article-title":"Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease","volume":"53","author":"Moro","year":"1999","journal-title":"Neurology"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861908000522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861908000522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T21:25:10Z","timestamp":1545773110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861908000522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":160,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0733861908000522"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2008.05.003","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}